Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma.
Phase of Trial: Phase I/II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Neuroblastoma vaccine (Primary) ; OPT 821 (Primary) ; Beta Glucans
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 15 Dec 2017 Planned number of patients changed from 145 to 215.
- 21 Nov 2016 Planned number of patients changed from 115 to 145.
- 03 May 2016 Planned End Date changed from 1 May 2016 to 1 May 2020.